Old Web
English
Sign In
Acemap
>
authorDetail
>
Bann-mo Day
Bann-mo Day
Medicine
Melanoma
Vemurafenib
Oncology
Internal medicine
4
Papers
28
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
BRAF V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study
2017
OncoTargets and Therapy
Allen Lee Cohn
Bann-mo Day
Sarang Abhyankar
Edward McKenna
Todd Riehl
Igor Puzanov
Show All
Source
Cite
Save
Citations (16)
Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
2016
Journal of Clinical Oncology
Johanna C. Bendell
Benjamin R. Tan
James Andrew Reeves
Henry Xiong
Bradley G. Somer
Heinz-Josef Lenz
Howard S. Hochster
Frank A. Scappaticci
Nicolas Sommer
Bann-mo Day
Herbert Hurwitz
Show All
Source
Cite
Save
Citations (10)
Iconography : Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib
2013
Journal of The American Academy of Dermatology
Anne Lynn S. Chang
James A. Solomon
John D. Hainsworth
Leonard Harry Goldberg
Edward McKenna
Bann-mo Day
Diana M. Chen
Glen J. Weiss
Show All
Source
Cite
Save
Citations (0)
A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.
2012
Journal of Clinical Oncology
Lynn M. Schuchter
Lawrence E. Flaherty
Omid Hamid
Gerald P. Linette
Sigrun Hallmeyer
Rene Gonzalez
Charles Lance Cowey
Anna C. Pavlick
Fred J. Kudrik
David H. Lawson
Kim Margolin
Antoni Ribas
David F. McDermott
James Khatcheressian
Keith T. Flaherty
Bann-mo Day
R. Linke
John D. Hainsworth
Show All
Source
Cite
Save
Citations (2)
1